Group One Trading
FDMT icon

Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
20,900
+2,000
+11% +$19.5K ﹤0.01% 4016
2026
Q1 		$176K Sell
18,900
-48,500
-72% -$422K ﹤0.01% 4220
2025
Q4 		$506K Buy
67,400
+26,800
+66% +$272K ﹤0.01% 3498
2025
Q3 		$353K Buy
40,600
+13,900
+52% +$83.1K ﹤0.01% 4057
2025
Q2 		$99.1K Buy
26,700
+5,300
+25% +$18.6K ﹤0.01% 4972
2025
Q1 		$69.1K Sell
21,400
-500
-2% -$2.36K ﹤0.01% 4906
2024
Q4 		$122K Buy
21,900
+10,500
+92% +$82.4K ﹤0.01% 4349
2024
Q3 		$123K Buy
11,400
+11,200
+5,600% +$186K ﹤0.01% 4005
2024
Q2 		$4.2K Sell
200
-5,200
-96% -$130K ﹤0.01% 6016
2024
Q1 		$172K Sell
5,400
-2,700
-33% -$68.9K ﹤0.01% 3694
2023
Q4 		$164K Buy
8,100
+8,000
+8,000% +$105K ﹤0.01% 4037
2023
Q3 		$1.27K Sell
100
-3,900
-98% -$65.2K ﹤0.01% 7170
2023
Q2 		$72.3K Buy
4,000
+2,400
+150% +$44.2K ﹤0.01% 4942
2023
Q1 		$27.5K Sell
1,600
-700
-30% -$13.6K ﹤0.01% 5305
2022
Q4 		$51.1K Buy
+2,300
New +$35.5K ﹤0.01% 4978
2022
Q1 		– Sell
-400
Closed -$9K – 8219
2021
Q4 		$9K Buy
+400
New +$9.8K ﹤0.01% 7393

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Group One Trading's FDMT Position: Q2 2026 in Review

Group One Trading sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 1,998 shares — an estimated $19.5K sold.

Group One Trading first reported a position in FDMT in Q4 2021 and held it in 8 quarters. The position peaked at $74.8K in Q4 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Group One Trading reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 1,998 4D Molecular Therapeutics shares in Q2 2026, an estimated $19.5K.
  • Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 8 quarters.
  • Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.